1. SLA – Pipeline Town Hall Ben Weintraub and Jeff Southwood
Adis R&D Insight
SLA – Pipeline Town Hall
Ben Weintraub and
Jeff Southwood
March 27, USA

2. Why Adis r&D insight
March 27, USA

3. Why? – Experience, Expertise, and Timeliness
Editorial Staff
150+ highly qualified (PhD, MD, PharmD) staff in-house
Average writing experience = 7-10 years (some up to 20 years)
Expertise across extensive range of therapeutic areas
Rigorous training program
Global focus
inThought Team
10 years experience covering pharma for Wall Street
Practicing physicians on staff to provide the clinician’s perspective
Network of medical experts
Daily updates from company contacts, press releases, international conferences, company websites, and journals
Comprehensive pipeline of preclinical, clinical, and launched compounds, updated daily using sources from around the world.
March 27, USA

4. Why? – Scientific/Clinical Emphasis
In-depth reviews of launched products and compounds in development worldwide covering all indications, countries, and phases
Concise summaries of pivotal clinical trials with links to full study profiles in Adis Clinical Trials Insight
Comprehensive drug development history provides timeline for key events and milestones throughout the development process
Detailed synopsis of pharmacokinetics, pharmacodynamics, and adverse events broken out by indication
Global phase of development table documents progress by country/region
Extensively referenced profiles provide a
narrative of each drug’s developmental history.
March 27, USA

5. Why? – inThought Commercial Assessments
inThought Approvability Index
Probability of FDA approval
Available for all drugs in active clinical development
Based on specific factors in each phase of clinical development and benchmarked against historical parameters
Absolute probability of approval as well as comparison to similar agents
Revenue Forecasts
Models assess both currently approved and developmental drugs
Top-down, based on the addressable patient population
Forecasts seven years in the future and three years in the past
Models incorporate Wolters Kluwer’s Healthcare Analytics prescription data
Single-source estimates provide a consistent view of
FDA approvability and worldwide revenue potential.
March 27, USA

6. 12 No Develop-ment Reported
Why? – Ease of Use
Intuitive search by name, class, mechanism, organization, development role, indication, patient segment, phase, and country
Refine search results to include drugs that are only available for licensing, small molecules, fixed combinations, orphan drugs, fast track status, biological, in active development
Save searches, send searches, revise searches
Alerts based on saved searches
Gilead Products by Phase
12 No Develop-ment Reported
17 Launched
28 Discontinued - Preclinical
10 Phase II
March 27, USA

7. Why? – Workflow Solution Tools
Create Excel and PowerPoint tables and graphs from search results
Export to Excel or HTML
Exported charts have links to the database that do not require a password – to anyone
March 27, USA

8. Why? – Customer Support
Ask-The-Expert service provides complimentary access to our team of scientific experts, financial analysts, and physician consultants to help answer your specific questions
March 27, USA

9. Emerging trends
March 27, USA

10. Emerging Trends
Pharma is increasing the pace and sophistication of licensing and acquisitions, driving a need for better information to screen candidates and more diverse and detailed information about each product
Emerging markets: visibility into India, China, and other emerging markets are becoming critical
Pharma doesn’t want a data dump…they need a strategic partner who can synthesize, condense, and summarize all the available information in a meaningful way that provides insights that are commercially relevant to their specific business and business issues
Mix of secondary and primary information, mix of facts and opinions
Drug database users want a single source for clinical data summaries, forecasts, commercial information, and business development solutions.
March 27, USA

11. Future Developments
March 27, USA

12. Future Development
Single site source for clinical, commercial, deals, and regulatory
Incorporate other content from within Wolters Kluwer
Sales and managed care content from Source Healthcare Analytics
Clinical Trial content from Adis Clinical Trials Insight
Epidemiology and clinical content from UpToDate
inThought Research alert content
Partner with 3rd parties for additional commercial content
Consensus revenue estimates
Consensus launch dates
Patent expiry
Building a single source for clinical data summaries, forecasts, commercial information, and business development solutions.
March 27, USA